Immureboost changes name to Fountain Healthy Aging

This approval follows the earlier approval of the name change by the board of directors and the shareholders of the company.

Tony Jimenez, CEO of Fountain Healthy Aging, said: “Fountain Healthy Aging will be a pioneer in the anti-aging industry with our new flagship product Vitalife. Vitalife is the world’s first and only transdermal growth hormone releasing hormone analog. Studies show statistically significant increases in hGH levels from baseline, after treatment with Vitalife.”

In the next few months, Fountain Healthy Aging will focus on transitioning Vitalife into the mass market. According to the company, the existing clinical data will be bolstered by five additional clinical trials conducted in countries around the world that will provide further evidence of the product’s safety and efficacy.